The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 06, 2024
Filed:
Oct. 28, 2020
Applicants:
Genfleet Therapeutics (Shanghai) Inc., Shanghai, CN;
Zhejiang Genfleet Therapeutics Co., Ltd., Shaoxing, CN;
Inventors:
Fusheng Zhou, Shanghai, CN;
Tao Jiang, Shanghai, CN;
Chonglan Lin, Shanghai, CN;
Lijian Cai, Shanghai, CN;
Wan He, Shanghai, CN;
Jiong Lan, Shanghai, CN;
Assignees:
Genfleet Therapeutics (Shanghai)Inc., Shanghai, CN;
Zhejiang Genfleet Therapeutics Co., Ltd., Shaoxing, CN;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/22 (2006.01); A61K 31/4985 (2006.01); A61K 31/5383 (2006.01); A61K 31/55 (2006.01); A61P 35/00 (2006.01); C07D 471/14 (2006.01); C07D 471/16 (2006.01); C07D 498/22 (2006.01);
U.S. Cl.
CPC ...
C07D 498/22 (2013.01); C07D 471/16 (2013.01); C07D 471/22 (2013.01);
Abstract
A substituted heterocyclic fused cyclic compound as represented by formula (I) or formula (IA) and having a selective inhibitory effect on KRAS gene mutation, or a pharmaceutically-acceptable salt, a stereoisomer, a solvate or a prodrug thereof, a pharmaceutical composition containing the compound, and an application thereof in preparation of cancer drugs are provided.